Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4921-4930 Newer>

Chemistry World June 18, 2008 Ananyo Bhattacharya	Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
The Motley Fool June 17, 2008 Brian Orelli	Change a Label, Change the Game For Teva Pharmaceutical, swapping the label on its Parkinson's drug, Azilect, could add hundreds of millions of dollars in sales per year.
The Motley Fool June 17, 2008 Brian Orelli	Acadia Gets Halved Acadia Pharmaceuticals loses half of the drugs in its clinical pipeline and half of its value in one day.
The Motley Fool June 16, 2008 Brian Orelli	More Cancer Issues for Johnson & Johnson Potential cancer-causing side effects of Johnson & Johnson's drugs are like a tumor that continues to grow on the company.
Chemistry World June 13, 2008 Richard Van Noorden	Asymmetric ketone catalysis gets pharma-scale makeover An asymmetric catalysis reaction limited to laboratory syntheses has received a makeover that could see it used on a large scale by drug-makers.
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
The Motley Fool June 13, 2008 Brian Orelli	China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.
The Motley Fool June 13, 2008 Brian Lawler	Novo Nordisk Bleeds a Little The pharmaceutical's hot streak ends as a vital study fizzles out.
<Older 4921-4930 Newer> Return to current articles.